13 July 2015

Notice of Pain Relief Portfolio Study Results

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, intends to announce the headline results from the clinical study of its portfolio of three topical pain relief products on Tuesday 14 July 2015 at 7.00am

A presentation for analysts will be held at 10.00am on 14 July 2015 at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN, to discuss the results of the study.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670
james.barder@futuramedical.com
angela.hildreth@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan
Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com